B7-1 Active Protein | CD80 active protein

B7-1 Protein, Cynomolgus, Recombinant (hFc Tag)

Cat. Num. AAA8123590

• Purity: >95% as determined by SDS-PAGE
• Synonyms: B7-1; B7-1 Protein; Cynomolgus; Recombinant (hFc Tag); Cynomolgus CD80/B7-1 Protein (Fc Tag); CD80 molecule; CD80 active protein

• Host: HEK293 Cells
• Purity/Purification: >95% as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, pH7.4. Normally 5%-8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
• Sequence: Met1-Asn242

• Species: Cynomolgus
• Endotoxin: <1.0EU per ug of the protein as determined by the LAL method
• Predicted N Terminal: Val 35
• Tag: C-human IgG1-Fc
• Protein Construction: A DNA sequence encoding the cynomolgus CD80 (AAC31555.1)(Met1-Asn242) was expressed with the Fc region of human IgG1 at the C-terminus.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
• Activity: Immobilized Cynomolgus CTLA4-His at 10ug/ml (100uL/well) can bind Cynomolgus CD80-Fc. The EC50 of CynomolgusCD80-Fc is 0.02-0.04ug/ml.
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -20 degree C to -80 degree C. Store it under sterile conditions at -20 degree C to -80 degree C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.; In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid.; They are shipped out with blue ice.

SDS-Page

Related Product Information for CD80 active protein

Background: The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Product Categories/Family for CD80 active protein

Cancer Drug Targets

References

Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418.Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9.Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.

NCBI and Uniprot Product Information

• Molecular Weight: The recombinant cynomolgus CD80 is a disulfide-linked homodimer. The reduced monomer comprises 449 amino acids and has a calculated molecular mass of 50.9kDa.The apparent molecular mass of the protein is approximately 65 and 44kDa respectively in SDS-PAGE
• Protein Family: T-lymphocyte activation antigen